Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma
Gang Xiao, Li-Lian Jin, Chaoqun Liu, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 146

Showing 26-50 of 146 citing articles:

EZH2 Inhibition: A Promising Strategy to Prevent Cancer Immune Editing
Ning Kang, Mark Eccleston, Pier‐Luc Clermont, et al.
Epigenomics (2020) Vol. 12, Iss. 16, pp. 1457-1476
Open Access | Times Cited: 54
Icaritin Induces Anti-tumor Immune Responses in Hepatocellular Carcinoma by Inhibiting Splenic Myeloid-Derived Suppressor Cell Generation
Huimin Tao, Mingyu Liu, Yuan Wang, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 53
EZH2 inhibits NK cell–mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner
Suresh Bugide, Romi Gupta, Michael R. Green, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 30
Open Access | Times Cited: 53
Pharmacological manipulation of Ezh2 with salvianolic acid B results in tumor vascular normalization and synergizes with cisplatin and T cell-mediated immunotherapy
Cheng Qian, Chunmei Yang, Yu Tang, et al.
Pharmacological Research (2022) Vol. 182, pp. 106333-106333
Closed Access | Times Cited: 35
SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1–PD-L1 axis
Kun Gao, Qing Shi, Ye Gu, et al.
Cell Death and Differentiation (2022) Vol. 30, Iss. 2, pp. 475-487
Open Access | Times Cited: 31
Synergistic effect of IFN-γ and IL-1β on PD-L1 expression in hepatocellular carcinoma
Yasunao Numata, Noriyuki Akutsu, Keisuke Ishigami, et al.
Biochemistry and Biophysics Reports (2022) Vol. 30, pp. 101270-101270
Open Access | Times Cited: 29
EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A
Ke Wang, Xunliang Jiang, Yu Jiang, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 21
Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition
Shengwei Tao, Shuhang Liang, Taofei Zeng, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 19
Combination of epidrugs with immune checkpoint inhibitors in cancer immunotherapy: From theory to therapy
Ruoyu Guo, Jixia Li, Jinxia Hu, et al.
International Immunopharmacology (2023) Vol. 120, pp. 110417-110417
Open Access | Times Cited: 18
Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1
Ana Dillen, Indy Bui, Megan Jung, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1237-1237
Open Access | Times Cited: 8
Roles of Interferon Regulatory Factor 1 in Tumor Progression and Regression: Two Sides of a Coin
Alina M. Perevalova, L. F. Gulyaeva, Vladimir O. Pustylnyak
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2153-2153
Open Access | Times Cited: 7
Contemporary clinical trials in pancreatic cancer immunotherapy targeting PD-1 and PD-L1
Ganji Purnachandra Nagaraju, Rama Rao Malla, Riyaz Basha, et al.
Seminars in Cancer Biology (2021) Vol. 86, pp. 616-621
Closed Access | Times Cited: 38
Polycomb Directed Cell Fate Decisions in Development and Cancer
Beatriz Germán, Leigh Ellis
Epigenomes (2022) Vol. 6, Iss. 3, pp. 28-28
Open Access | Times Cited: 27
Demethylase JMJD2D induces PD-L1 expression to promote colorectal cancer immune escape by enhancing IFNGR1-STAT3-IRF1 signaling
Qiang Chen, Shuqing Zhuang, Yilin Hong, et al.
Oncogene (2022) Vol. 41, Iss. 10, pp. 1421-1433
Closed Access | Times Cited: 25
WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma
Alexander Rialdi, Mary E. Duffy, Alex P. Scopton, et al.
Nature Cancer (2023) Vol. 4, Iss. 8, pp. 1157-1175
Open Access | Times Cited: 15
PD-L1-mediated immune evasion in triple-negative breast cancer is linked to the loss of ZNF652
Yuncheng Liu, Peng Yuan, Wei Du, et al.
Cell Reports (2023) Vol. 42, Iss. 11, pp. 113343-113343
Open Access | Times Cited: 15
An anoikis-based signature for predicting prognosis in hepatocellular carcinoma with machine learning
Guizhen Zhang, Zhu Weiwei, Yun Wang, et al.
Frontiers in Pharmacology (2023) Vol. 13
Open Access | Times Cited: 14
HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma
Chen Shen, Mei Li, Yujuan Duan, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 14
Lysine N-methyltransferase SETD7 promotes bladder cancer progression and immune escape via STAT3/PD-L1 cascade
Jiancheng Lv, Qikai Wu, Kai Li, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 12, pp. 3744-3761
Open Access | Times Cited: 14
The current status and future of PD-L1 in liver cancer
Liyuan Hao, Shenghao Li, Jiali Deng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 14
Current understanding of cancer-intrinsic PD-L1: regulation of expression and its protumoral activity
Pedram Yadollahi, Youkyoung Jeon, Wooi Loon Ng, et al.
BMB Reports (2021) Vol. 54, Iss. 1, pp. 12-20
Open Access | Times Cited: 31
Reversing Post-Infectious Epigenetic-Mediated Immune Suppression
Abhimanyu Abhimanyu, Carlos O. Ontiveros, Rosa S. Guerra-Resendez, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 30
Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
Zhitao Li, Guoqiang Sun, Guangshun Sun, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 30
Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance
Jamaal L. James, Brandie C. Taylor, Margaret L. Axelrod, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 11, pp. e007736-e007736
Open Access | Times Cited: 11
A prognostic and immune related risk model based on zinc homeostasis in hepatocellular carcinoma
Yifei Shi, Runxin Ye, Yuan Gao, et al.
iScience (2024) Vol. 27, Iss. 4, pp. 109389-109389
Open Access | Times Cited: 4

Scroll to top